Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Victory and defeat at Heraclea - treating hepatitis C infection following liver transplantation with telaprevir and boceprevir.

Charlton M, Dick T.

J Hepatol. 2014 Jan;60(1):6-8. doi: 10.1016/j.jhep.2013.10.006. Epub 2013 Oct 12. No abstract available.

2.

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.

Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC.

J Hepatol. 2014 Jan;60(1):78-86. doi: 10.1016/j.jhep.2013.08.018. Epub 2013 Aug 29.

PMID:
23994384
3.

Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation.

Ikegami T, Yoshizumi T, Shirabe K, Maehara Y.

J Hepatol. 2014 Apr;60(4):894-6. doi: 10.1016/j.jhep.2013.10.037. Epub 2013 Dec 4. No abstract available.

4.

Reply to: "Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation".

Coilly A, Sebagh M, Duclos-Vallée JC.

J Hepatol. 2014 Apr;60(4):896-7. doi: 10.1016/j.jhep.2013.11.032. Epub 2013 Dec 4. No abstract available.

5.

Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.

Sitole M, Silva M, Spooner L, Comee MK, Malloy M.

Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 Jan 29.

PMID:
23369368
6.

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J.

J Viral Hepat. 2012 May;19 Suppl 2:1-26. doi: 10.1111/j.1365-2893.2012.01590.x. Review.

PMID:
22404758
7.

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

Swiss Association for the Study of the Liver.

Swiss Med Wkly. 2012 Feb 24;142:w13516. doi: 10.4414/smw.2012.13516. Review.

8.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
9.

Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.

Chevaliez S.

Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S46-51. doi: 10.1016/S2210-7401(11)70007-9.

PMID:
22248694
10.

Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).

Italian Association for the Study of the Liver (AISF), Coco B, Caraceni P, Aghemo A, Bitetto D, Bruno R, Ciancio A, Marzioni M, Petta S, Rendina M, Valenti L; Review Board:.

Dig Liver Dis. 2014 Jan;46(1):18-24. doi: 10.1016/j.dld.2013.08.243. Epub 2013 Oct 9. Review.

11.

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA.

J Hepatol. 2013 Jul;59(1):31-7. doi: 10.1016/j.jhep.2013.02.018. Epub 2013 Feb 27.

PMID:
23454058
12.

Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation.

Reddy KR, Everson GT.

Hepatology. 2013 Sep;58(3):1181-4. doi: 10.1002/hep.26612. Epub 2013 Jul 31. No abstract available.

PMID:
23908010
13.

A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.

Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N.

Ann Hepatol. 2012 Mar-Apr;11(2):179-85. Review.

14.

Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.

Gambarin-Gelwan M, Jacobson IM.

Curr Gastroenterol Rep. 2012 Feb;14(1):47-54. doi: 10.1007/s11894-011-0237-1. Review.

PMID:
22161022
15.

Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.

Saxena V, Terrault N.

Curr Opin Organ Transplant. 2012 Jun;17(3):216-24. doi: 10.1097/MOT.0b013e3283534d64. Review.

PMID:
22476221
16.

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.

Blázquez-Pérez A, San Miguel R, Mar J.

Pharmacoeconomics. 2013 Oct;31(10):919-31. doi: 10.1007/s40273-013-0080-3.

PMID:
24000086
17.

Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.

Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.

Antivir Ther. 2011;16(5):695-704. doi: 10.3851/IMP1821.

PMID:
21817191
18.

[Telaprevir in treatment-naïve patients with HCV monoinfection].

Cabezas J, Crespo J, Selmo J, Luis Calleja J.

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:7-13. doi: 10.1016/S0213-005X(13)70118-6. Review. Spanish.

PMID:
24063897
19.

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.

Asselah T.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):455-62. doi: 10.1016/j.bpg.2012.09.003.

PMID:
23199504
20.

[Efficacy of the NS3-4A protease inhibitor telaprevir in patients with chronic hepatitis C].

Ozeki I, Karino Y, Toyota J.

Nihon Rinsho. 2011 May;69 Suppl 4:267-74. Japanese. No abstract available.

PMID:
22096930
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk